Cargando…

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy

OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Restelli, Umberto, Saibene, Gabriella, Nardulli, Patrizia, Di Turi, Roberta, Bonizzoni, Erminio, Scolari, Francesca, Perrone, Tania, Croce, Davide, Celio, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642784/
https://www.ncbi.nlm.nih.gov/pubmed/28765126
http://dx.doi.org/10.1136/bmjopen-2016-015645
_version_ 1783271427670016000
author Restelli, Umberto
Saibene, Gabriella
Nardulli, Patrizia
Di Turi, Roberta
Bonizzoni, Erminio
Scolari, Francesca
Perrone, Tania
Croce, Davide
Celio, Luigi
author_facet Restelli, Umberto
Saibene, Gabriella
Nardulli, Patrizia
Di Turi, Roberta
Bonizzoni, Erminio
Scolari, Francesca
Perrone, Tania
Croce, Davide
Celio, Luigi
author_sort Restelli, Umberto
collection PubMed
description OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC). SETTING: Oncology hospital department in Italy. METHODS: A Markov model was used to determine the impact of NEPA on the budget of the Italian NHS on a 5-day time horizon, corresponding to the acute and delayed CINV prophylaxis phases. Direct medical costs considered were related to antiemetic drugs, adverse events management, CINV episodes management. Clinical and quality of life data referred to previously published works. The budget impact analysis considered the aforementioned therapies plus PALO alone (for HEC and MEC) on a 5-year time horizon, comparing two scenarios: one considering the use of NEPA and one not considering its use. PRIMARY AND SECONDARY OUTCOME MEASURES: Incremental cost per quality adjusted life year (QALY) and differential economic impact for the Italian NHS between the two scenarios considered. RESULTS: NEPA is more effective and less expensive (dominant) compared with APR + PALO (for HEC and MEC), fAPR + PALO (for HEC and MEC), APR + ONDA (for HEC), fAPR + ONDA (for HEC). The use of NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for HEC and €20.9 million for MEC). CONCLUSIONS: NEPA allows an efficient allocation of resources for the Italian NHS and it is sustainable, leading to a cost decrease compared with a scenario which does not consider its use.
format Online
Article
Text
id pubmed-5642784
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56427842017-10-25 Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy Restelli, Umberto Saibene, Gabriella Nardulli, Patrizia Di Turi, Roberta Bonizzoni, Erminio Scolari, Francesca Perrone, Tania Croce, Davide Celio, Luigi BMJ Open Health Economics OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC). SETTING: Oncology hospital department in Italy. METHODS: A Markov model was used to determine the impact of NEPA on the budget of the Italian NHS on a 5-day time horizon, corresponding to the acute and delayed CINV prophylaxis phases. Direct medical costs considered were related to antiemetic drugs, adverse events management, CINV episodes management. Clinical and quality of life data referred to previously published works. The budget impact analysis considered the aforementioned therapies plus PALO alone (for HEC and MEC) on a 5-year time horizon, comparing two scenarios: one considering the use of NEPA and one not considering its use. PRIMARY AND SECONDARY OUTCOME MEASURES: Incremental cost per quality adjusted life year (QALY) and differential economic impact for the Italian NHS between the two scenarios considered. RESULTS: NEPA is more effective and less expensive (dominant) compared with APR + PALO (for HEC and MEC), fAPR + PALO (for HEC and MEC), APR + ONDA (for HEC), fAPR + ONDA (for HEC). The use of NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for HEC and €20.9 million for MEC). CONCLUSIONS: NEPA allows an efficient allocation of resources for the Italian NHS and it is sustainable, leading to a cost decrease compared with a scenario which does not consider its use. BMJ Publishing Group 2017-08-01 /pmc/articles/PMC5642784/ /pubmed/28765126 http://dx.doi.org/10.1136/bmjopen-2016-015645 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Health Economics
Restelli, Umberto
Saibene, Gabriella
Nardulli, Patrizia
Di Turi, Roberta
Bonizzoni, Erminio
Scolari, Francesca
Perrone, Tania
Croce, Davide
Celio, Luigi
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title_full Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title_fullStr Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title_full_unstemmed Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title_short Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
title_sort cost-utility and budget impact analyses of the use of nepa for chemotherapy-induced nausea and vomiting prophylaxis in italy
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642784/
https://www.ncbi.nlm.nih.gov/pubmed/28765126
http://dx.doi.org/10.1136/bmjopen-2016-015645
work_keys_str_mv AT restelliumberto costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT saibenegabriella costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT nardullipatrizia costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT dituriroberta costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT bonizzonierminio costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT scolarifrancesca costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT perronetania costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT crocedavide costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly
AT celioluigi costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly